Tag - APRE

Developments

Aprea announces IP expansion for precision oncology programs

Aprea Therapeutics (NASDAQ: APRE) has announced an expansion of its intellectual property (IP) portfolio for precision oncology programs. According to Aprea, the company has strengthened its global IP portfolio with 28...

August 28, 2026

Markets

HCW starts Aprea Therapeutics at neutral; PT $30

H.C. Wainwright initiated coverage of Aprea Therapeutics (NASDAQ:APRE) with a “neutral” rating and $30 price target. The stock closed at $37.90 on June 19. “We see more downside risk heading into pivotal data,” writes...

June 22, 2020

Developments

Aprea Therapeutics updates Phase 1b/2 eprenetapopt trial results

Aprea Therapeutics (NASDAQ:APRE) reported updated data from its Phase 1b/2 trial evaluating eprenetapopt, in combination with azacytidine, for the treatment of myelodysplastic syndromes (MDS) and acute myeloidleukemia...

June 12, 2020

Developments

Aprea Therapeutics gets breakthrough therapy designation for myelodysplastic syndrome treatment

Aprea Therapeutics (NASDAQ:APRE) received FDA breakthrough designation for APR-246, in combination with azacytidine, for the treatment of myelodysplastic syndromes (MDS) with a susceptible tumor suppressor protein p53...

January 30, 2020

Tag - APRE

Aprea announces IP expansion for precision oncology programs

HCW starts Aprea Therapeutics at neutral; PT $30

Aprea Therapeutics updates Phase 1b/2 eprenetapopt trial results

Aprea Therapeutics gets breakthrough therapy designation for myelodysplastic syndrome treatment

Subscribe